TrialCell reports. Medicine2024

Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL).

Yuchen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.